Ropinirole Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

21 Suppliers, 12 USDMF, 6 CEP/COS, 4 JDMF, 8 EU WC, 5 KDMF, 10 NDC API, 11 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

3 Suppliers

3 Suppliers

DOSSIERs // Finished Dosage Forms

227 Dossiers, 138 FDA Orange Book, 65 Europe, 12 Canada, 5 South Africa, 7 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 0.25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 12MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 39 Kerry, 23 Roquette, 23 BASF, 17 SPI Pharma, 17 Microlex e.U, 13 Seppic, 12 Corel Pharma Chem, 11 Sigachi Industries, 11 Gangwal Chemicals, 10 Gangwal Healthcare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 Nanjing Well Pharmaceutical, 7 Ideal Cures Pvt Ltd, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 6 Actylis, 6 Lonza Capsugel, 6 DFE Pharma, 5 Kima Chemical, 4 The Dow Chemical Company, 4 Ingredion Pharma Solutions, 3 Rochem International Inc, 3 Boai NKY Pharmaceuticals Ltd, 3 Prachin Chemical, 3 Vasa Pharmachem, 2 Nomisma Healthcare, 2 Pharmatrans-Sanaq, 2 DKSH, 2 Seqens, 2 Finar, 2 Ulanqab Kema New Material, 2 Jai Radhe Sales, 1 Nanjing Bold Chemical, 1 ACG Worldwide, 1 Qualicaps, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Aeon Procare, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Clariant, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Alcedo Pharmachem, 1 Vertellus, 1 Pfanstiehl

EXCIPIENTS BY APPLICATIONS

91 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 40 Direct Compression, 36 Controlled & Modified Release, 30 Solubilizers, 27 Granulation, 26 Thickeners and Stabilizers, 24 Disintegrants & Superdisintegrants, 21 Taste Masking, 20 Film Formers & Plasticizers, 18 Parenteral, 18 Lubricants & Glidants, 17 Co-Processed Excipients, 16 Chewable & Orodispersible Aids, 15 Topical, 9 Emulsifying Agents, 8 API Stability Enhancers, 7 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 2 Coloring Agents

GLOBAL SALES INFORMATION

25 US Medicaid Prescriptions, 58 Finished Drug Prices

MARKET PLACE

3 APIs

3 APIs

PATENTS

18 Health Canada Patents

18 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 1 USP Standards, 2 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow, 1 News

Latest U.S. Prescription Data for Drugs containing Ropinirole Hydrochloride under Medicare's Part D Prescription Drug Program. Original Data: Centers for Medicare & Medicaid Services Website

Ropinirole Hydrochloride

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

21 Suppliers

12 USDMF

6 CEP/COS

4 JDMF

8 EU WC

5 KDMF

10 NDC API

11 Listed Suppliers

PRICE INFORMATION

API Reference Price

API Exports

API Imports

INTERMEDIATES

3 Suppliers

DOSSIERs // Finished Dosage Forms

227 Dossiers

138 FDA Orange Book

65 Europe

12 Canada

5 South Africa

7 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 0.25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 12MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

39 Kerry

23 Roquette

23 BASF

17 SPI Pharma

17 Microlex e.U

13 Seppic

12 Corel Pharma Chem

11 Sigachi Industries

11 Gangwal Chemicals

10 Gangwal Healthcare

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 Nanjing Well Pharmaceutical

7 Ideal Cures Pvt Ltd

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

6 Actylis

6 Lonza Capsugel

6 DFE Pharma

5 Kima Chemical

4 The Dow Chemical Company

4 Ingredion Pharma Solutions

3 Rochem International Inc

3 Boai NKY Pharmaceuticals Ltd

3 Prachin Chemical

3 Vasa Pharmachem

2 Nomisma Healthcare

2 Pharmatrans-Sanaq

2 DKSH

2 Seqens

2 Finar

2 Ulanqab Kema New Material

2 Jai Radhe Sales

1 Nanjing Bold Chemical

1 ACG Worldwide

1 Qualicaps

1 Qianhao Chemical (Hebei) Co., Ltd

1 Aeon Procare

1 Shijiazhuang Huaxu Pharmaceutical

1 Clariant

TABLET;ORAL - EQ 0.25MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 0.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 1MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 4MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 12MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 4MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons